• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA approves first generic moxidectin injectable solution for cattle parasite treatment

March 30, 2023
dvm360 Staff

Tauramox is the first generic moxidectin injectable solution to control internal and external parasites

The US Food and Drug Administration (FDA) has just approved Tauramox as the first generic moxidectin injectable solution indicated for "beef and nonlactating dairy cattle for the treatment and control of internal and external parasites in cattle."1 Tauramox is an antiparasitic drug that contains the same concentration of moxidectin in the same injectable dosage form as the approved brand name drug product, Cydectin, which was first approved on May 20, 2005. As with Cydectin, residues in food products derived from beef and nonlactating dairy cattle treated with Tauramox will not represent a public health concern when the product is used according to the label.1

The FDA advises that the rate of administration for Tauramox Injectable is 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight. Tauramox will now be available over the counter and supplied in a 10 mg/ml concentration in 250 and 500 mL bottles.

The FDA strongly advises that when administering Tauramox, veterinary professionals be careful to estimate the animal’s body weight as closely as possible. This is important to avoid overdosing or underdosing the animal in order to ensure each animal receives a complete dose based on a current body weight. According to the FDA, underdosing may result in ineffective treatment and encourage the development of parasite resistance.1

When administered at the correct dosage, Tauramox is effective at treating and controlling the following parasites in cattle:

Advertisement
  • Gastrointestinal Roundworms
  • Lungworms
  • Cattle Grubs
  • Mites
  • Lice

For specific species, go to: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13677

Referenece

FDA approves first generic moxidectin injectable solution for the treatment and control of parasites in cattle. News release. US Food and Drug Administration. March 30, 2023. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-moxidectin-injectable-solution-treatment-and-control-parasites-cattle?utm_medium=email&utm_source=govdelivery

Related Content:

FDAPharmacy
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease

Advertisement

Latest News

Four ways to curb no shows

FDA and European Union expand Mutual Recognition Agreement to include animal drugs

Successful tolerability study of CBD products for dogs

Second annual 'Dog Days of Summer' adoption event to take place in Michigan

View More Latest News
Advertisement